title: HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression.
abstract: BACKGROUND
  Abnormalities in Human Leukocyte Antigen (HLA) class I expression are common in colorectal cancer. Since HLA expression is required to activate tumor antigen-specific cytotoxic T-lymphocytes (CTL), HLA class I abnormalities represent a mechanism by which tumors circumvent immune surveillance. Tumors with high microsatellite instability (MSI-H) are believed to face strong selective pressure to evade CTL activity since they produce large amounts of immunogenic peptides. Previous studies identified the prevalence of HLA class I alterations in MSI-H tumors. However, those reports did not compare the frequency of alterations between hereditary and sporadic MSI-H tumors neither the mechanisms that led to HLA class I alterations in each subgroup.
  
  
  METHODS
  To characterize the HLA class I expression among sporadic MSI-H and microsatellite-stable (MSS) tumors, and HNPCC tumors we compared immunohistochemically the expression of HLA class I, beta2-microglobulin (beta2m), and Antigen Processing Machinery (APM) components in 81 right-sided sporadic and 75 HNPCC tumors. Moreover, we investigated the genetic basis for these changes.
  
  
  RESULTS
  HLA class I loss was seen more frequently in MSI-H tumors than in MSS tumors (p < 0.0001). Distinct mechanisms were responsible for HLA class I loss in HNPCC and sporadic MSI-H tumors. Loss of HLA class I expression was associated with beta2m loss in HNPCC tumors, but was correlated with APM component defects in sporadic MSI-H tumors (p < 0.0001). In about half of the cases, loss of expression of HLA class I was concordant with the detection of one or more mutations in the beta2m and APM components genes.
  
  
  CONCLUSIONS
  HLA class I aberrations are found at varying frequencies in different colorectal tumor types and are caused by distinct genetic mechanisms. Chiefly, sporadic and hereditary MSI-H tumors follow different routes toward HLA class I loss of expression supporting the idea that these tumors follow different evolutionary pathways in tumorigenesis. The resulting variation in immune escape mechanisms may have repercussions in tumor progression and behavior.
authors.affiliation: Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. JWFDierssen@gmail.com <JWFDierssen@gmail.com>
authors.forename: Jan Willem F
authors.initials: JW
authors.lastname: Dierssen
authors.forename: Noel F C C
authors.initials: NF
authors.lastname: de Miranda
authors.forename: Soldano
authors.initials: S
authors.lastname: Ferrone
authors.forename: Marjo
authors.initials: M
authors.lastname: van Puijenbroek
authors.forename: Cees J
authors.initials: CJ
authors.lastname: Cornelisse
authors.forename: Gert Jan
authors.initials: GJ
authors.lastname: Fleuren
authors.forename: Tom
authors.initials: T
authors.lastname: van Wezel
authors.forename: Hans
authors.initials: H
authors.lastname: Morreau
mesh_terms: D000368:Aged; D003110:Colonic Neoplasms / Q000235:genetics* / Q000276:immunology*; D003123:Colorectal Neoplasms, Hereditary Nonpolyposis / Q000235:genetics* / Q000276:immunology*; D005260:Female; D005805:Genes, MHC Class I / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D053842:Microsatellite Instability; D008875:Middle Aged; D019139:Tumor Escape